(Q35818185)

10 August 2017

1 reference

title

On the horizon: possible neuroprotective role for glatiramer acetate (English)

1 reference

10 August 2017

Rivka Riven Kreitman

1

1 reference

10 August 2017

François Blanchette

series ordinal

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Multiple Sclerosis Journal

10 August 2017

published in

1 reference

10 August 2017

volume

10 Suppl 1

1 reference

10 August 2017

page(s)

S81-6; discussion S86-9

1 reference

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Inflammation in multiple sclerosis: the good, the bad, and the complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Effector pathways in immune mediated central nervous system demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Brain-derived neurotrophic factor in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1037OA

10.1191/1352458504MS1037OA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference